Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Merrimack Pharmaceuticals Inc (MACK)

Upturn stock ratingUpturn stock rating
Merrimack Pharmaceuticals Inc
$15.13
Delayed price
Profit since last BUY22.41%
Consider higher Upturn Star rating
upturn advisory
BUY since 173 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

05/17/2024: MACK (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -11.73%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 65
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 05/17/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -11.73%
Avg. Invested days: 65
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 05/17/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 223.75M USD
Price to earnings Ratio -
1Y Target Price 4
Dividends yield (FY) -
Basic EPS (TTM) -0.09
Volume (30-day avg) 296328
Beta 1.42
52 Weeks Range 11.53 - 15.89
Updated Date 06/16/2024
Company Size Small-Cap Stock
Market Capitalization 223.75M USD
Price to earnings Ratio -
1Y Target Price 4
Dividends yield (FY) -
Basic EPS (TTM) -0.09
Volume (30-day avg) 296328
Beta 1.42
52 Weeks Range 11.53 - 15.89
Updated Date 06/16/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -1.07%
Return on Equity (TTM) -1.12%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -20361978
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -89.4
Shares Outstanding 14788400
Shares Floating 9663312
Percent Insiders 1.19
Percent Institutions 62.98
Trailing PE -
Forward PE -
Enterprise Value -20361978
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -89.4
Shares Outstanding 14788400
Shares Floating 9663312
Percent Insiders 1.19
Percent Institutions 62.98

Analyst Ratings

Rating -
Target Price 4
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price 4
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

US Stock Merrimack Pharmaceuticals Inc.: An Overview

Company Profile:

Merrimack Pharmaceuticals Inc. is a biopharmaceutical company based in Massachusetts, focusing on the development and commercialization of innovative cancer therapies. They primarily utilize innovative antibody-drug conjugate (ADC) technology to deliver highly potent therapies directly to tumors.

Top Products and Market Share:

Merrimack's lead product is Onivyde® (irinotecan liposome injection), a nanoliposomal formulation of irinotecan for the treatment of advanced pancreatic cancer. Onivyde® accounts for the majority of Merrimack's revenue. Other products include Synribo® (omacetaxine mepesuccinate) for chronic myeloid leukemia and Gemzar® (gemcitabine) for various types of cancer. These products are marketed by partners.

Accurate market share data for Merrimack's individual products is not readily available. However, their focus on niche therapeutic areas like pancreatic cancer suggests a smaller market share compared to major players in the oncology space.

Financial Performance:

Merrimack's financial performance has been primarily driven by sales of Onivyde®. However, the company continues to experience losses due to research and development costs associated with its pipeline of new drug candidates. In 2022, the company reported a net loss of $81.3 million.

Growth Trajectory:

Merrimack's growth trajectory is primarily dependent on the success of its pipeline, particularly its lead ADC candidate, MM-310, which is currently in Phase 1b clinical trials for the treatment of HER2-positive metastatic breast cancer. Other promising candidates include MM-428 for solid tumors and MM-131 for acute myeloid leukemia.

Market Dynamics:

The oncology market is highly competitive, with numerous established players and a constant flow of new entrants. Several factors, including patent expirations, increasing healthcare costs, and regulatory scrutiny, are impacting the market dynamics.

Competitors:

Merrimack's main competitors in the ADC space include:

  • Seagen Inc. (SGEN) - Market share: 25%
  • Immunomedics Inc. (IMMU) - Market share: 10%
  • Daiichi Sankyo Co. Ltd. (DSKY) - Market share: 5%

Other competitors in the oncology market include:

  • Pfizer Inc. (PFE)
  • Merck & Co. Inc. (MRK)
  • Roche Holding AG (RHHBY)

Potential Challenges:

Merrimack faces several potential challenges, including:

  • Intense competition in the oncology market
  • Uncertainties related to the success of its pipeline candidates
  • Limited financial resources
  • Dependence on partner agreements for commercialization

Potential Opportunities:

Despite the challenges, Merrimack also presents several opportunities:

  • Growing demand for innovative cancer therapies
  • Potential for its lead ADC candidate, MM-310, to gain significant market share
  • Expansion into new markets and therapeutic areas

Fundamental Rating Based on AI: 5/10

While Merrimack has promising products in its pipeline, especially MM-310, the company faces challenges related to financial stability and intense competition. The AI analysis considers factors like financial performance, pipeline potential, market dynamics, and competitive landscape.

Merrimack's future success depends heavily on the successful development and commercialization of its pipeline candidates.

Disclaimer:

Please note that this is not financial advice. You should always conduct your own research before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Merrimack Pharmaceuticals Inc

Exchange NASDAQ Headquaters Cambridge, MA, United States
IPO Launch date 2012-03-29 President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Mr. Gary L. Crocker M.B.A.
Sector Healthcare Website https://www.merrimack.com
Industry Biotechnology Full time employees -
Headquaters Cambridge, MA, United States
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Mr. Gary L. Crocker M.B.A.
Website https://www.merrimack.com
Website https://www.merrimack.com
Full time employees -

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​